复发性卵巢癌PARP抑制剂卓越应答者的长期结局
国际多中心回顾性队列纳入320例铂敏感复发性卵巢癌PARP抑制剂卓越应答者(无进展生存≥5年),中位随访6.8年,中位用药75.0个月。7.5年与10年无进展生存率分别为88.8%与78.7%,迟发MDS/AML仅5例(1.6%);因非进展原因停药者10年无进展生存率90.1%,高于持续用药者的72.5%。
要点
- 卓越应答者10年无进展生存率达78.7%,迟发MDS/AML风险低(1.6%)。
- 因非进展原因停药者10年无进展生存率90.1%,高于持续用药者的72.5%。
- 卓越应答者富集BRCA1 RING域与BRCA2 DNA结合域变异。
核心结论
- PARP抑制剂卓越应答者多数长期无进展,包括非进展原因停药者,迟发MDS/AML风险低。
- 结果可用于指导卓越应答者维持治疗时长的咨询,并提示铂敏感复发性卵巢癌可能实现功能性治愈。
研究设计与样本
- 国际多中心回顾性队列研究,覆盖14个国家41个中心,时间自2023年1月11日至2025年11月10日。
- 卓越应答定义为铂敏感复发性卵巢癌自启动PARP抑制剂起无进展生存≥5年,共纳入320例,平均(SD)年龄56.4(9.4)岁。
- 主要终点为无进展生存,次要终点包括总生存、毒性反应与剂量下调。
主要发现
- 中位随访6.8年(95%CI,6.6-7.0年),PARP抑制剂中位(IQR)用药时长75.0(64.0-91.0)个月。
- 211例(65.9%)持续用药,109例(34.1%)停药:医生建议34例(10.6%)、5年后疾病进展2例(7.5%)、毒性反应22例(6.9%)、患者意愿17例(5.3%)、其他原因12例(3.8%)。
- 7.5年与10年无进展生存率分别为88.8%(95%CI,84.5%-93.3%)与78.7%(95%CI,70.5%-87.9%)。
- 85例(26.6%)因非疾病进展原因停药,其10年无进展生存率90.1%(95%CI,80.6%-100%),持续用药者为72.5%(95%CI,60.3%-87.2%)。
- 5例(1.6%)诊断为迟发MDS/AML;卓越应答者富集BRCA1 RING域与BRCA2 DNA结合域变异。
关键数值与推荐
- 卓越应答定义:铂敏感复发性卵巢癌自PARP抑制剂启动起无进展生存≥5年。
- 7.5年与10年无进展生存率分别为88.8%(95%CI,84.5%-93.3%)与78.7%(95%CI,70.5%-87.9%)。
- 非进展原因停药者与持续用药者的10年无进展生存率分别为90.1%(95%CI,80.6%-100%)与72.5%(95%CI,60.3%-87.2%)。
临床怎么用
- 对已达5年无进展的卓越应答者,可依据低迟发MDS/AML风险与停药后仍高的无进展生存率个体化讨论维持治疗时长。
- 因毒性或患者意愿停药后仍需长期随访,关注超过5年的迟发进展与MDS/AML。
- BRCA1 RING域与BRCA2 DNA结合域变异或有助于识别卓越应答人群。
局限性
- 为回顾性队列研究,存在选择偏倚与停药原因混杂,非进展停药者与持续用药者的比较非随机。
- 卓越应答定义限定无进展生存≥5年,结论不能外推至未达此标准的PARP抑制剂治疗人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A subset of patients with platinum-sensitive recurrent ovarian cancer (PS-ROC) treated with maintenance poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have exceptional response. Although licensing recommends continuing PARP inhibitors until progression or unacceptable toxic effects, the optimal duration of PARP inhibitors, and the risks of late progression, myelodysplastic syndrome (MDS), or acute myeloid leukemia (AML) in patients with exceptional response are unknown. OBJECTIVE: To determine the long-term outcomes of patients with PS-ROC who have exceptional response to PARP inhibitors, and to explore genotype-phenotype associations. DESIGN, SETTING, AND PARTICIPANTS: This was an international, multicenter, retrospective cohort study of patients with exceptional response to PARP inhibitors, defined as patients with PS-ROC and progression-free survival (PFS) of 5 years or longer from PARP inhibitor commencement. The study was conducted across 41 sites in 14 countries from January 11, 2023, to November 10, 2025. EXPOSURES: Treatment with PARP inhibitors. MAIN OUTCOMES AND MEASURES: The primary end point was PFS, and secondary end points included overall survival, toxic effects, and dose reductions. RESULTS: A total of 320 patients with exceptional response (mean [SD] age, 56.4 [9.4] years) were included, with a median follow-up of 6.8 years (95% CI, 6.6-7.0 years). The median (IQR) PARP inhibitor duration was 75.0 (64.0-91.0) months. Of patients with exceptional response, 211 (65.9%) received continuous PARP inhibitors, but 109 (34.1%) discontinued: 34 (10.6%) due to physician recommendation, 2 (7.5%) had disease progression beyond 5 years, 22 (6.9%) had toxic effects, 17 (5.3%) for patient preference, and 12 (3.8%) for another reason. The 7.5-year and 10-year PFS rates were 88.8% (95% CI, 84.5%-93.3%) and 78.7% (95% CI, 70.5%-87.9%), respectively. Among the patients, 85 (26.6%) discontinued PARP inhibitors for reasons other than disease progression, with a 10-year PFS of 90.1% (95% CI, 80.6%-100%) vs 72.5% (95% CI, 60.3%-87.2%) for those who continued taking PARP inhibitors. Five patients (1.6%) were diagnosed with late-onset MDS/AML. Patients with exceptional response were enriched for variants in the BRCA1 RING domain and the BRCA2 DNA-binding domain. CONCLUSIONS AND RELEVANCE: In this cohort study, most patients with exceptional response to PARP inhibitors remained progression free, including those who discontinued PARP inhibitors without progression. The risk of late-onset MDS/AML was low. These results can guide counseling on the duration of maintenance PARP inhibitors in patients with exceptional response and suggest that functional cure may be possible in patients with PS-ROC and exceptional response to PARP inhibitors.
引用
- Haggstrom L, Lee YC, Barretina-Ginesta MP, et al. Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors. JAMA Oncol. 2026. PMID: 42348196. doi:10.1001/jamaoncol.2026.1924
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。